Research Article
Antimicrobial Therapy as a Risk Factor of Multidrug-Resistant Acinetobacter Infection in COVID-19 Patients Admitted to the Intensive Care Unit
Table 3
Basic characteristics of the patients.
| | Variable | MDR-Ab infection | No MDR-Ab infection |
| | Quantitative variables | Median (25th percentile, 75th percentile) | | Age (years) | 66 (56, 70) | 64 (50, 70) | | C-reactive protein (mg/L) | 130 (76, 170) | 112 (65, 149) | | Glomerular filtration rate (ml/s) | 1.32 (0.87, 1.59) | 1.24 (0.96, 1.48) | | Neutrophil count (×1000 cells/ml) | 7.45 (4.85, 13.29) | 7.69 (4.46, 12.04) | | Lymphocyte count (×1000 cells/ml) | 0.74 (0.48, 1.34) | 0.79 (0.54, 1.36) | | CD4+ lymphocyte count (cells/ml) | 285 (180, 462) | 300 (160, 430) | | Length of ICU stay | 13 (6, 18) | 6 (4, 9) |
| | Categorical variables | n/n total (%) | | Diabetes mellitus | 13/33 (39.39%) | 19/57 (33.33%) | | Obesity | 19/33 (57.58%) | 38/57 (49.12%) | | Male gender | 21/33 (63.63%) | 36/57 (63.16%) | | Tocilizumab therapy | 13/33 (39.39%) | 7/57 (12.28%) | | Previous exposure to ceftriaxone | 20/33 (60.60%) | 17/57 (29.82%) | | Previous exposure to meropenem | 6/33 (18.18%) | 9/57 (15.78%) | | Mechanical ventilation | 20/33 (60.60%) | 22/57 (38.60%) | | Death | 17/33 (51.52%) | 21/57 (36.84%) |
|
|
in univariate analysis. ICU: intensive care unit; MDR-Ab: multidrug-resistant Acinetobacter. |
